The KRAS gene gives cells instructions for a signaling protein that helps control when cells grow, divide, and respond to outside messages. If this gene becomes overactive, cells may keep getting a growth signal, which can contribute to cancer and, less often, certain conditions present from birth. In medicine, this gene is important because it helps regulate pathways often involved in colorectal, lung, and pancreatic cancers. KRAS is especially well known in cancer care because tumor testing often looks for KRAS variants to help guide treatment choices.
What is a gene?
Genes are stretches of DNA that carry instructions your cells use to make molecules or regulate processes in the body. Some genes hold the information needed to produce proteins, the parts of cells that do much of the work. Other genes mainly guide when certain processes happen, where they happen, and how strongly they run. Together, genes affect how the body develops and functions, and they can also shape how you respond to food, stress, or medications. For a more detailed look at this topic, you can find additional information in the LearnHub.
Overview
KRASGene function
What if the gene works
The KRAS gene helps control how cells grow, divide, and respond to signals from their surroundings. It acts like an on off switch inside cells, supporting normal development and routine tissue repair.
Risk
What if the gene does not work
Variants in the KRAS gene can drive cancers, especially in the lung, colon, and pancreas. Inherited variants can also cause a Noonan spectrum condition, with effects ranging from milder features to earlier or noticeable heart, growth, skin, or learning differences.
Treatment
What does that mean for your treatment
Pathogenic variants in the KRAS gene can directly shape cancer treatment choices. In metastatic colorectal cancer, a KRAS variant means anti-EGFR drugs such as cetuximab and panitumumab are not expected to help on their own. In advanced non-small cell lung cancer with KRAS G12C, targeted drugs such as sotorasib or adagrasib may be options.
Conditions associated with KRAS
Gene function
What if the gene works
Your cells use the KRAS gene to pass along signals that tell them when to grow, divide, and mature. It helps everyday communication inside the body stay timely and well coordinated. Understanding how the KRAS gene works in the body helps explain how cells respond to normal growth cues.
The KRAS gene helps carry messages from the cell surface to the cell’s control center. These messages start when cells detect normal growth signals from their surroundings.
Its protein acts like a switch that turns signaling on for a short time and then back off. This helps cells grow and divide in a controlled, orderly way.
The KRAS gene supports pathways that help cells decide whether to divide, mature, or stay in their current state. This keeps routine tissue growth and renewal moving in a coordinated way.
What is a variant?
Within a gene, a genetic variant means there is a slight difference in the DNA sequence. Variants are common and are one reason people naturally differ in features such as appearance, metabolism, and how the body reacts to environmental influences. Many do not lead to any noticeable change and are simply part of normal genetic variation. In some situations, though, a variant affects how a gene works more strongly and may contribute to or directly cause a genetic condition.
Genetic variants
What if the gene does not work
Most disease-causing changes in the KRAS gene make its signaling protein stay stuck in the “on” position, so cells keep receiving growth messages when they should pause. This is central to how KRAS gene variants affect cell growth signaling. Some variants only mildly raise signaling, while others have a stronger effect on protein activity, which can influence how early a condition linked to the KRAS gene appears and how marked its features are.
How variants are linked to conditions
Acquired KRAS gene variants linked to cancer are common in pancreatic, colorectal, and lung cancers. Rare inherited pathogenic variants in the KRAS gene can cause Noonan syndrome and, less often, cardiofaciocutaneous syndrome. In cancer, a variant in the KRAS gene is usually limited to the tumor, so it often helps classify the cancer rather than showing an inherited condition.
A variant is not necessarily a diagnosis
Variants in genes are a normal feature of human biology and are common throughout the general population. Most have no direct impact on health and simply reflect natural human diversity. For many genes, carrying a variant connected with a condition suggests a possible association rather than a definite diagnosis, especially when several genes and environmental factors also contribute. In some situations, though, a single well-characterized variant in a specific gene is enough to confirm a diagnosis.
Are there things that can increase or change my risk?
For inherited changes in the KRAS gene, risk is usually driven mainly by the genetic change itself rather than by lifestyle. There is not enough evidence to say that diet, exercise, or supplements lower this risk, but regular medical follow-up can help find and manage related health problems early.
Inheritance of KRAS variants
For people learning about the KRAS gene inheritance pattern, KRAS-related inherited conditions are usually passed down in an autosomal dominant way. This means one changed copy of the KRAS gene can be enough to cause the condition, and a parent who carries it can pass it to each child with a 50% chance. Some people have a new, de novo variant in the KRAS gene, which means it started in them and was not inherited from either parent. Because the KRAS gene is on chromosome 12, it can be inherited by sons and daughters equally.
What does my KRAS result mean for my family?
Some changes in the KRAS gene can cause inherited conditions such as Noonan syndrome or related conditions in a dominant pattern, so close relatives like parents, siblings, and children may also carry the same change. In many families, each child of someone with a disease-causing KRAS change has a 1 in 2, or 50%, chance of inheriting it. Some KRAS changes happen for the first time in a child, so a parent is not always the source.
Genetic information
Genetic testing
How you find out about variants
Genetic testing for variants in the KRAS gene uses a blood, saliva, or tumor sample, depending on the reason for testing. A laboratory reads the DNA in that sample to look for a variant in the KRAS gene and reports whether the result may help confirm a diagnosis, guide cancer treatment choices, or inform family testing.
When should I consider getting a genetic test?
Consider KRAS testing if you have a cancer such as colon or lung cancer where tumor testing can help guide treatment, or if a child has signs of an inherited condition such as Noonan syndrome. The right test depends on whether doctors are looking for a change in the tumor or a change that runs in the family.
A genetic result is only one part of your health story
Genetic findings can offer useful insight, but what they show depends on the condition and on the type of variant involved. Age, environment, lifestyle, and medical history are among the many factors that shape how the body works over time. In some conditions, especially those influenced by many genes, genetic information provides context rather than certainty and is best understood together with other parts of care. In other situations, a genetic result may give a clear answer. In areas like medication response, genetic results can help put individual experiences into context.
Pharmacogenetics
How variants shape your response to medicine
Variants in the KRAS gene in a tumor can help predict whether EGFR targeted cancer medicines such as cetuximab or panitumumab are likely to work, especially in colorectal cancer. When a KRAS variant is present, these medicines are much less likely to help because the cancer cell may keep sending growth signals even when the drug blocks the EGFR pathway. More broadly, genetic variation can influence medication response in different ways, including how a drug is processed or how strongly a drug target responds. This is one reason the same treatment can work well for one person but less well for another, or cause different side effects.
What is Pharmacogenetics?
Pharmacogenetics is the area of study that examines how genetic differences affect a person’s response to medications. It looks at the relationship between genes and drugs to help explain why the same treatment may work differently from one person to another. For many medicines, genes influence how strongly a drug works or how the body handles it. This understanding can support treatment decisions that are more informed and more individualized. More information about this topic is available in the LearnHub.
Drugs influenced by the KRAS gene
When should I seek medical advice?
There is not yet a broadly confirmed role for this gene in routine inherited drug-response decisions, so general medication concerns are best discussed with your doctor. KRAS is different in cancer care: changes found in a tumor can help guide some targeted treatment choices. If you are being treated for colorectal or lung cancer, your cancer team may discuss KRAS tumor results before starting or changing treatment.
History
The KRAS gene became historically important in the early 1980s, when cancer research was rapidly changing. Scientists found that KRAS was part of the RAS family, a group of genes that helped explain how normal cells can become cancer cells after a harmful variant appears. First described in the scientific literature as part of early genetics, it was identified through studies of tumor viruses and later matched to a human gene. This discovery helped establish the idea of the “oncogene,” meaning a gene that can drive cancer when altered. From these first observations, research expanded steadily. KRAS remains one of the best-known genes in the history of cancer genetics.